HOPKINTON, Mass., Sept. 2 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. , a leading provider of tools and services for drug discovery and life sciences research, today announced that, as anticipated, researchers using the LabChip(R) EZ Reader(TM) platform for screening and profiling kinase inhibitors now have access to more than 200 kinase assays. The assays are available in Caliper’s ProfilerPro(TM) reagent format, a pre-packaged, ready-to-use kit that enables in-house kinase profiling to be performed in a single day.
Each of Caliper’s ProfilerPro Kinase Selectivity Assay Kits contain all necessary reagents and controls for rapidly profiling up to 12 different compounds against 24 protein kinases per kit; and now more than 200 kinases are available in this format. All necessary reagents are pre-dispensed into reaction-ready 384 well microtiter plates to simplify workflows and accelerate time to results. ProfilerPro reagent kits are analyzed using proprietary microfluidic LabChip assay technology.
“Caliper’s unique same-day kinase profiling platform enables researchers to make better compounds by providing chemists faster access to more information about potential off target liabilities,” said Rick Bunch, business unit manager, LabChip Systems, Caliper Life Sciences. “The combination of high quality data generated by LabChip microfluidic assays with workflow improvements inherent to ProfilerPro reagents means that overall drug discovery programs can be accelerated, enabling companies to bring drugs to market faster.”
Caliper’s EZ Reader series, a suite of instruments for screening and profiling kinase inhibitors and performing kinetic mechanism-of-action studies, utilizes microfluidic separation and direct detection of both substrates and products to generate high quality, reproducible data to qualify potential lead candidates. Caliper provides researchers in oncology and inflammation therapeutic areas with platforms and services for target validation; biochemical screening and profiling; cancer cell panels for drug combinations, monotherapy and isogenic analysis; and in vivo efficacy studies using IVIS technology for subcutaneous, orthotropic, and metastatic tumor models; and in vivo pharmacodynamic analysis.
Caliper also today separately announced the availability of RapidKinase profiling service from Caliper Discovery Alliances and Services (CDAS), the company’s contract research organization. This service offering incorporates Caliper’s LabChip EZ Reader technology and ProfilerPro reagents. (Additional details can be found in the press release “Caliper Life Sciences Launches RapidKinase(TM) Profiling Services and Mechanism of Action(TM) Studies.” http://www.caliperls.com/about/news-media-center/press-releases/)
Caliper offers a broad portfolio of Lab Chip drug discovery and separation systems. For additional information or to order the EZ Reader platform, please visit: http://www.caliperls.com/products/labchip-systems/.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper, LabChip, EZ Reader, ProfilerPro, RapidKinase and Mechanism of Action are trademarks of Caliper Life Sciences, Inc.
CONTACT: Jeff Benanto or Tim Pitta of Schwartz Communications, for Caliper
Life Sciences, Inc., +1-781-684-0770, caliper@schwartz-pr.com
Web site: http://www.caliperls.com/
